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DOI: 10.1039/c2md00269hNovel ionic liquids containing ampicillin as an active pharmaceutical ingredient anion were prepared
with good yields by using a new, efficient synthetic procedure based on the neutralization of
a moderately basic ammonia solution of ampicillin with different organic cation hydroxides. The
relevant physical and thermal properties of these novel ionic liquids based on ampicillin were also
evaluated.Introduction
Ionic liquids (ILs) are generally defined as organic salts with
melting points below 100 C (some of them are liquid at room
temperature) and composed entirely of ions.1,2 The large number
of possible cation/anion combinations allows for a great variety
of tuneable interactions and subsequent applications.1,3,4 Ionic
liquids were initially used as greener alternatives to conventional,
toxic and volatile organic solvents.1,5 Some properties generally
attributed to ILs, such as high thermal and electrochemical
stability, negligible vapour pressure,3,6 high ionic conductivity,3
non-flammability and a tuneable solvation capacity, encouraged
their application across a wide range of areas, including organic
chemistry,1,4 chemical engineering,1,3 materials science,3,7 phys-
ical chemistry,3,8,9 analytical chemistry,3,10 and
biotechnology.1,3,11,12
Recently, ILs have been combined with active pharmaceutical
ingredients (APIs), and a so-called third generation of ILs has
emerged.13 These IL–API compounds offer new and improved
properties, such as stability, solubility, permeability and drug
delivery, as compared to the corresponding solid pharmaceutical
forms. The use of an active drug in the liquid form (at room
temperature) can avoid some of the issues of polymorphism
associated with crystalline solids and, thus, dramatically influ-
ence the drug’s solubility and dosages.1,14,15However, the entry of
ILs into the biosciences has been delayed mainly because of theaDepartamento de Quımica, REQUIMTE-CQFB, Faculdade de Cie^ncias e
Tecnologia da Universidade Nova de Lisboa, 2829-516 Caparica, Portugal.
E-mail: z.petrovski@fct.unl.pt; l.branco@fct.unl.pt; imarrucho@itqb.unl.
pt; Fax: +351 21 294 85 50
bCie^ncias Quımicas e das Biomoleculas, Escola Superior de Tecnologia da
Saude do Porto do Instituto Politecnico do Porto, Portugal
cInstituto de Tecnologia Quımica e Biologica, Universidade Nova de
Lisboa, Apartado 127, 2780-157 Oeiras, Portugal; Web: www.itqb.unl.pt
dCentro de Farmacologia e Biopatologia Quımica (U38-FCT), Faculdade
de Medicina da Universidade do Porto, Alameda Prof. Herna^ni Monteiro,
4200-319 Porto, Portugal
† Electronic supplementary information (ESI) available. See DOI:
10.1039/c2md00269h
494 | Med. Chem. Commun., 2012, 3, 494–497toxicity of the counterions.1 Most recent communications and
reviews refer to the toxicity and activity of ILs against micro-
organism and cell cultures, especially their antimicrobial activity
as well as drug delivery performance.1,15–18 ILs have recently been
tested in the fight against multi-drug resistance18,19 and even
against microbial biofilms, showing a broad and powerful spec-
trum of activities against several microbial pathogens, including
Methicillin-resistant Staphylococcus aureus. The recent outbreak
of E. coli O104 (ref. 20 and 21) in Germany as well as the
appearance of multi-drug-resistant organisms such as Gram-
negative Enterobacteriaceae given by the New Delhi metallo
b-lactamase22–24 are becoming increasingly serious public health
problems worldwide. Thus, the discovery of alternative and
efficient pathways for the treatment of infections is one of the
most urgent challenges of this century. Novel therapies using ILs
as a drug delivery device1 offer interesting avenues for
exploration.
From the pharmaceutical point of view, the possibility of
eliminating the negative side effects of a given active compound
by delivering it as an IL–API is extremely attractive. Taking
advantage of the IL properties, the counter-ion can be meticu-
lously selected in order to minimize those undesirable side effects
or to open up novel treatment therapies in which two active ions
are paired.
Results and discussion
This work intended to develop an efficient, synthetic method-
ology for preparing several ILs–APIs based on ampicillin [Amp].
Ampicillin has always been used as an anion combined with the
following organic cations: 1-ethyl-3-methylimidazolium
[EMIM], 1-hydroxy-ethyl-3-methylimidazolium [C2OHMIM],
choline [cholin], tetraethylammonium [TEA], cetylpyridinium
[C16pyr] and trihexyltetradecylphosphonium [P6,6,6,14]. These
anions were chosen due to their low toxicity, except in the case of
[P6,6,6,14] which was chosen to ensure that an IL–API in the liquid
form could be obtained. The combination of the adequate anion
or cation with a specific drug can lead to an alteration in theThis journal is ª The Royal Society of Chemistry 2012
Scheme 1 Schematic synthetic procedure for the preparation of ampicillin-based ILs.
Fig. 1 Structure of cations used.
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View Article Onlinecompound’s biopharmaceutical drug classification25 as well as its
drug formulation process.
The most conventional synthetic preparation of ILs involves
a metathesis reaction of an anion halide with an adequate alka-
line salt and this was also used in the preparation of some bulky
imidazolium and pyridinium ILs containing an ampicillin
anion.26 The pure IL can be obtained by eliminating undesirable
inorganic salts (mainly sodium, potassium or lithium chloride or
bromide) using precipitation followed by filtration.27 The need to
obtain pure ILs, especially halide-free ones, has been one of the
central concerns within the IL community. The use of inorganic
acids instead of salts is a potential approach to reducing these
inorganic contaminations.28 In the case of a large number of
inorganic or organic anions, alternatives need to be considered,
due to the fact that an anion exchange by weaker acids than
hydrohalic acids29 cannot be efficiently performed. In the case of
imidazolium cations, Earle and Seddon proposed the use of
imidazole carbenes30 as strong bases. Nevertheless, this process is
restricted to imidazolium cations, due to the high reactivity and
low stability of the carbene intermediate.28
Ion exchange resin methods recently developed by Ohno
et al.31 are being successfully used as alternative anion exchange
processes and they have been extended to other reactions.
Amberlite resin (in the OH form) has been used in order to
exchange halides (bromide or chloride) to the hydroxide form
and then this basic solution is neutralized by the addition of an
adequate acid solution. The acid–base reaction yields the desired
salt or IL.28,29,31 Our first attempt to use this anion exchange
method failed due to ampicillin’s poor solubility in most
common organic solvents (with the exception of DMSO), as well
as the instability of the b-lactam ring in the presence of strong
bases. The decomposition of ampicillin was always detected by
NMR analysis after several attempts.
The initial synthetic procedure was modified by dissolving
ampicillin in a moderately basic ammonia solution and then
neutralizing it with different hydroxides prepared with the Ohno
method. Using an ammonia solution buffer (pH ¼ 11.6), the
hydrolysis of the sensitive b-lactam ring by a possible hydroxide
attack was avoided. Pure ILs–APIs based on ampicillin structure
were obtained after eliminating the excess ammonia and/orThis journal is ª The Royal Society of Chemistry 2012ampicillin by evaporation and crystallization respectively. The
organic cations were selected from substituted ammonium,
phosphonium, pyridinium and methylimidazolium salts which
were first transformed into hydroxides by the use of an ionic
exchange column (Amberlite IRA-400 OH) in methanol.31 The
prepared hydroxides were then neutralized with the b-lactam
antibiotic (Scheme 1).
The structures of the anions and the cations synthesised and
studied in this work appear in Fig. 1.
All isolated products were completely characterized by 1H and
13C NMR, FTIR and ESI mass spectra in order to check their
expected structures and final purities. NMR studies also eluci-
date the expected cation/anion correlations by a quantitative
integration of their characteristic 1H resonance peaks. Experi-
mental and characterization details about prepared ILs–APIs are
included as the ESI†.
Physical properties
Table 1 summarizes some properties of the synthesized ILs–APIs
based on ampicillin. Our optimized synthetic procedure allowed
us to obtain pure compounds in high yields (75 to 95%). All
compounds are soluble in methanol, ethanol and water (except
[P6,6,6,14][Amp]). It is important to emphasize that the use of
appropriate ammonium and imidazolium cations can effectively
change the initial trihydrate ampicillin water solubility
(6 mg mL1) and consequently its potential membrane
permeability.Med. Chem. Commun., 2012, 3, 494–497 | 495
Table 1 Physical properties of ILs–APIs based on ampicillin
Compound Yield (%)a [a]27D
b/
Solubility
Misciblec Immisciblec
[TEA][Amp] 76.0 +48.7  2.5 MeOH, EtOH, iPrOH, H2O, Ac, AcOEt(pm)
[P6,6,6,14][Amp]
d 80.0 +23.3  1.5 MeOH, EtOH, iPrOH, Ac, AcOEt H2O
[C16Pyr][Amp] 76.4 +51.7  0.9 MeOH, EtOH, iPrOH Ac, AcOEt, H2O(pm)
[Cholin][Amp] 70.7 +52.3  0.8 MeOH, EtOH, H2O iPrOH, Ac, AcOEt
[EMIM][Amp] 94.6 +89.3  5.5 MeOH, EtOH, iPrOH, H2O Ac, AcOEt(pm)
[C2OHMIM][Amp] 86.8 +86.3  4.5 MeOH, EtOH, H2O iPrOH(pm), Ac, AcOEt(pm)
a Isolated yields. b Optical rotation values measured in methanol (2 mg mL1) by polarimetry at 27 C. c Observed complete solubilisation (miscible),
partial solubilisation (pm) or non-solubilisation (immiscible) by adding solvent to a small amount of ionic liquid, MeOH (methanol), EtOH (ethanol),
iPrOH (iso-propanol), Ac (acetone) and AcOEt (ethyl acetate). d The water content of [P6,6,6,14][Amp] was 14.7 ppm (determined by Karl Fisher
titration).
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View Article Online[Cholin][Amp] and [C2OHMIM][Amp] are immiscible in iso-
propanol contrary to other ILs–APIs. [P6,6,6,14][Amp] is the only
IL–API completely miscible in acetone and ethyl acetate.
Optical rotation values of the prepared ILs–APIs based on
ampicillin (+23.3  1.5 to +89.3  4.5 in methanol, Table 1) are
significantly lower compared with the initial trihydrate ampicillin
(+163.0  2.0 in water) but are of the same order of magnitude
as commercial sodium ampicillin (+40.0  4.0). The highest
optical rotations of the prepared compounds were observed
when imidazolium cation structures were used.Fig. 2 Comparative 1H NMR study of [cholin][Amp] for four temper-
atures (25, 45, 65 and 85 C) and twoNMR regions (1 to 2 ppm and 6.5 to
8.8 ppm) in DMSO.Thermal properties
The thermal properties of synthesized ILs–APIs based on
ampicillin are summarized in Table 2.
All the ILs–APIs were obtained as pale yellow solids (melting
temperature (Tm) between 58
C and 86 C) except in the case of
[P6,6,6,14][Amp] (viscous yellow liquid). [C2OHMIM][Amp] was
obtained as a yellow molten salt (Tm ¼ 117 C). Particularly
relevant is the successful reduction of the initial melting point of
commercial ampicillin or sodium ampicillin (higher than 300 C)
by the appropriate selection of organic cations. The glass tran-
sition temperature (Tg) was determined at a heating/cooling rate
of 1 C min1 for all compounds. Similar values of glass transi-
tion temperatures were detected for all ILs–APIs (17.86 C to
20.84 C) except in the case of [P6,6,6,14][Amp].
In the case of [P6,6,6,14][Amp], DSC curves showed two tran-
sition peaks at low temperature which can be attributed to
crystallization (80.07 C) and melting (23.01 C) processes,
respectively.Table 2 Thermal properties (Tm, Tg and Tdec) of ILs-APIs based on ampici
Compound Physical state
[TEA][Amp] Pale yellow solid
[P6,6,6,14][Amp] Yellow viscous liquid
[C16Pyr][Amp] Pale yellow solid
[Cholin][Amp] Pale yellow solid
[EMIM][Amp] Pale yellow solid
[C2OHMIM][Amp] Pale yellow solid
a Melting temperature (Tm) was determined by a melting point apparatus (Stua
measurements at a heating/cooling rate of 1 C min1 for all ILs. c Decompo
496 | Med. Chem. Commun., 2012, 3, 494–497Decomposition studies were performed by TGA analysis for
all the synthesized compounds. As expected, these studies indi-
cated that the selection of the organic cation influences the
thermal stability of ILs–APIs based on ampicillin. [P6,6,6,14]
[Amp] and [C16Pyr][Amp] presented higher thermal stability than
those ILs–APIs based on imidazolium and ammonium cations.llin
Tm
a/C Tg
b/C Tdec
c/C
79.0 18.64 214.75
— — 297.65
86.0 19.64 269.39
58.0 20.12 221.29
72.0 17.86 239.64
117.0 20.84 246.40
rt Scientific). b Glass transition temperature (Tg) was determined by DSC
sition temperature (Tdec) was determined by TGA studies.
This journal is ª The Royal Society of Chemistry 2012
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View Article OnlineNMR studies
A preliminary 1H NMR study was performed in the case of IL
[cholin][Amp] for different temperatures (25 C to 85 C). Fig. 2
illustrates a comparative 1H NMR study of [cholin][Amp] at four
temperatures (25, 45, 65 and 85 C) in d-DMSO. Two different
regions of the 1H NMR spectra between 1 to 2 ppm and 6.5 to
8.8 ppm were particularly selected to check the aliphatic (methyl
peaks) and aromatic (phenyl peaks) signals of the ampicillin
anion, respectively.
In the case of two methyl peaks (1.10 and 1.41 ppm) of
ampicillin, a chemical shift to the left was observed between
25 C and 85 C. This variation of the chemical shift (at least
0.04 ppm of difference between 25 C and 85 C) can be
explained by the possible interaction of the carboxylate group of
the ampicillin anion with the choline cation.
In the case of the aromatic peaks from ampicillin (7.20 to 7.50),
no significant variation of chemical shift was observed, indicating
that the phenyl ring of ampicillin does not interact with the
choline cation.Conclusions
The present work reports a new and efficient method for the
synthesis of b-lactam antibiotics like ampicillin, which may prove
useful for the development of new bioactive materials1 (anti-
septics and anti-biofilm, for example) or to reduce drug resis-
tance in microorganisms. With the careful selection of the
organic cation, it is possible to provoke important physical and
thermal properties of ILs–APIs based on ampicillin, such as
water solubility, melting point and thermal stability. [Cholin]
[Amp] is the most interesting example of a prepared API–IL in
what concerns its particular IL properties – low melting point
(see Table 2), very high water solubility, as well as the biocom-
patibility and low toxicity of the choline cation and therefore
probably will be most useful and interesting in further medicinal
investigation.Acknowledgements
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